Lista de obras -

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

artículo científico publicado en 2007

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding

artículo científico publicado en 2009

Association of SF-36 with coronary artery disease risk factors and mortality: a PreCIS study

artículo científico publicado en 2010

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance

artículo científico publicado en 2010

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

artículo científico publicado en 2008

Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

artículo científico publicado en 2014

Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry

artículo científico publicado en 2009

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

artículo científico publicado en 2008

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

artículo científico publicado en 2006

Comparing SF-36® scores versus biomarkers to predict mortality in primary cardiac prevention patients.

artículo científico publicado en 2017

Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.

artículo científico publicado en 2014

Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death

artículo científico publicado en 2010

Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study

artículo científico publicado en 2013

Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk

artículo científico publicado en 2009

Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions

Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial

artículo científico publicado en 2010

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

artículo científico

Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study

artículo científico publicado en 2008

High school body mass index and body mass index at entry to a cardiac disease risk prevention clinic and the association to all-cause mortality and coronary heart disease: a PreCIS database study

artículo científico publicado en 2010

Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study

artículo científico publicado en 2011

In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis

artículo científico publicado en 2003

Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

artículo científico publicado en 2012

Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials

artículo científico publicado en 2002

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

artículo científico publicado en 2007

Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy

artículo científico publicado en 2010

Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention

artículo científico publicado en 2006

Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial

artículo científico publicado en 2007

Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS)

artículo científico publicado en 2015

Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial

artículo científico publicado en 2009

Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis

artículo científico publicado en 2014

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

artículo científico publicado en 2008

Reply: To PMID 23983044

artículo científico publicado en 2014

Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis

artículo científico publicado en 2010

Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study

artículo científico publicado en 2008

Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation

artículo científico publicado en 2009

Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease

artículo científico publicado en 2006

Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition

artículo científico publicado en 2009

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial

artículo científico publicado en 2017

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

artículo científico publicado en 2008

The impact of left ventricular size on response to cardiac resynchronization therapy

artículo científico publicado en 2011

The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study

artículo científico publicado en 2009

Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting

artículo científico publicado en 2004

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience

artículo científico publicado en 2013

Use of Sex-Specific Clinical and Exercise Risk Scores to Identify Patients at Increased Risk for All-Cause Mortality

artículo científico publicado en 2016

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

artículo científico

Lista de obras de

An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial

Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding

Association of SF-36 with coronary artery disease risk factors and mortality: a PreCIS study

Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance

Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction

Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the united states: insights from the REACH Registry

Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosc

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Comparing SF-36® scores versus biomarkers to predict mortality in primary cardiac prevention patients.

Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.

Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death

Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study

Diminished global arginine bioavailability and increased arginine catabolism as metabolic profile of increased cardiovascular risk

Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions

Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial

Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study

High school body mass index and body mass index at entry to a cardiac disease risk prevention clinic and the association to all-cause mortality and coronary heart disease: a PreCIS database study

Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study

In-hospital initiation of lipid-lowering therapy after coronary intervention as a predictor of long-term utilization: a propensity analysis

Is there a clinically significant interaction between calcium channel antagonists and clopidogrel?: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials

Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial

Lipoprotein(a) levels and long-term cardiovascular risk in the contemporary era of statin therapy

Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention

Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial

Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS)

Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial

Relationship between metabolic syndrome and carotid intima-media thickness: cross-sectional comparison between psoriasis and psoriatic arthritis

Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk

Reply: To PMID 23983044

Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis

Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study

Subclinical myocardial necrosis and cardiovascular risk in stable patients undergoing elective cardiac evaluation

Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease

Targeted metabolomic evaluation of arginine methylation and cardiovascular risks: potential mechanisms beyond nitric oxide synthase inhibition

The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

The impact of left ventricular size on response to cardiac resynchronization therapy

The lipid accumulation product and all-cause mortality in patients at high cardiovascular risk: a PreCIS database study

Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting

Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience

Use of Sex-Specific Clinical and Exercise Risk Scores to Identify Patients at Increased Risk for All-Cause Mortality

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial